Inclusion Criteria

- INCLUSION CRITERIA:

ALPS Patients without Lymphoma:

Participants must:

1. Fulfill current criteria for the diagnosis of ALPS as follows:

1. Documented chronic nonmalignant lymphadenopathy and/or splenomegaly, and

2. Greater than or equal to 1.5 percent TCR alpha/beta+ CD4- CD8- T cells in the
peripheral blood.

2. Be enrolled in ALPS Natural History Protocol 93-I-0063.

3. Have clinical evidence of lymphadenopathy as defined by multiple palpable lymph nodes
of at least 1cm or radiographic evidence of lymphadenopathy as defined by multiple
lymph nodes of at least 1 cm on CT scan, during an evaluation at the NIH Clinical
Center.

4. Be 8 years of age or older. The study will be targeted to children 8 years of age or
older and adults because younger children may not be able to stay still for the
duration of the FDG-PET scan procedure. Sedation will not be used in children in
this study, except for clinically indicated procedures such as FDG-PET scans in
children with lymphoma.

5. Be due for their routine [every 2 years] CT scan under protocol 93-I-0063, or be in
need of a CT scan for medical reasons [e.g. marked change in adenopathy]. CT scan
within 3 months prior to FDG-PET scan is necessary to locate the nodes for
appropriate FDG-PET analysis.

ALPS Patients with Lymphoma:

Patients must:

1. Fulfill current criteria for the diagnosis of ALPS as follows:

1. Documented chronic nonmalignant lymphadenopathy and/or splenomegaly.

2. Greater than or equal to 1.5 percent TCR alpha/beta + CD4- CD8 -T cells in the
peripheral blood.

2. Be enrolled in ALPS Natural History Protocol 93-I-0063.

3. Have a histologically proven diagnosis of lymphoma, confirmed by the Laboratory of
Pathology, NCI (Anatomic Pathology Dept, CC) whether yet treated or not. Lymphomas
will be classified according to the WHO classification, using appropriate
immunophenotypic and histological features.

EXCLUSION CRITERIA:

1. Patient will be excluded if any of the following are present:

2. Concurrent infection or inflammatory disease (e.g., sarcoidosis), which itself often
shows increased FDG uptake by PET and which could interfere with the interpretation
of study results.

3. Active neoplasia other than lymphoma.

4. History of chemotherapy or radiation treated malignancy within 5 years prior to study
procedure, except for lymphoma.

5. Hyperglycermia (regardless of etiology) determined by fasting glucose of greater than
130 mg/dl. Individual with an underlying defect of glucose metabolism may exhibit
abnormal metabolism of FDG.

6. Weights in excess of 136 kg, which will exceed the weight limit for the scanner
table.

7. Pregnancy and breast-feeding. For women of childbearing potential, a negative urine
or serum pregnancy test is required within 24 hours prior to an FDG-PET scan.